{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:21:37Z","timestamp":1790014897049,"version":"4.0.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03768-z","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:09:27Z","timestamp":1759493367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["SGLT2 inhibitors for delaying diabetic retinopathy: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"45","author":[{"given":"Saba","family":"Goodarzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezah","family":"Soltani Abhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelareh","family":"Azarinoush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammd Ali","family":"Rafiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessam","family":"Yousefian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edris","family":"Ekramipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosar","family":"Namakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Shafiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"issue":"1","key":"3768_CR1","doi-asserted-by":"crossref","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA et al (2020) Diabetic retinopathy preferred practice pattern\u00ae. Ophthalmology 127(1):P66\u2013P145","journal-title":"Ophthalmology"},{"issue":"4","key":"3768_CR2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00125-023-06068-2","volume":"67","author":"AG Hoek","year":"2024","unstructured":"Hoek AG, Dal Canto E, Wenker E, Bindraban N, Handoko ML, Elders PJ et al (2024) Epidemiology of heart failure in diabetes: a disease in disguise. Diabetologia 67(4):574\u2013601","journal-title":"Diabetologia"},{"issue":"3","key":"3768_CR3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Yau","year":"2012","unstructured":"Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3):556\u2013564","journal-title":"Diabetes Care"},{"key":"3768_CR4","doi-asserted-by":"crossref","first-page":"1077669","DOI":"10.3389\/fendo.2022.1077669","volume":"13","author":"T-E Tan","year":"2023","unstructured":"Tan T-E, Wong TY (2023) Diabetic retinopathy: looking forward to 2030. Front Endocrinol 13:1077669","journal-title":"Front Endocrinol"},{"issue":"11","key":"3768_CR5","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham Y-C, Yu M, Chee ML, Rim TH, Cheung N et al (2021) Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology 128(11):1580\u20131591","journal-title":"Ophthalmology"},{"issue":"14","key":"3768_CR6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"Control D, Group CTR","year":"1993","unstructured":"Control D, Group CTR (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977\u2013986","journal-title":"N Engl J Med"},{"key":"3768_CR7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s40265-018-0937-z","volume":"78","author":"JE Frampton","year":"2018","unstructured":"Frampton JE (2018) Empagliflozin: a review in type 2 diabetes. Drugs 78:1037\u20131048","journal-title":"Drugs"},{"issue":"11","key":"3768_CR8","doi-asserted-by":"crossref","first-page":"9637","DOI":"10.1007\/s11033-023-08836-0","volume":"50","author":"B Xu","year":"2023","unstructured":"Xu B, Li S, Kang B, Fan S, Chen C, Li W et al (2023) Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitors response. Mol Biol Rep 50(11):9637\u20139647","journal-title":"Mol Biol Rep"},{"issue":"7","key":"3768_CR9","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","volume":"37","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ et al (2014) Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37(7):1815\u20131823","journal-title":"Diabetes Care"},{"issue":"3","key":"3768_CR10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC et al (2015) Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38(3):420\u2013428","journal-title":"Diabetes Care"},{"issue":"4","key":"3768_CR11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrcardio.2016.35","volume":"13","author":"I Raz","year":"2016","unstructured":"Raz I, Cahn A (2016) SGLT2 inhibitors and heart failure\u2014clinical implications. Nat Rev Cardiol 13(4):185\u2013186","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"3768_CR12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00417-023-06273-0","volume":"262","author":"JB Nadelmann","year":"2024","unstructured":"Nadelmann JB, Miller CG, McGeehan B, Yu Y, VanderBeek BL (2024) SGLT2 inhibitors and diabetic retinopathy progression. Graefes Arch Clin Exp Ophthalmol 262(3):753\u2013758","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3768_CR13","volume":"42","author":"JT George","year":"2019","unstructured":"George JT, Zinman B (2019) Retinopathy outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. Diabetes Care 42:e53","journal-title":"Diabetes Care"},{"issue":"10","key":"3768_CR14","volume":"14","author":"Y-R Chung","year":"2019","unstructured":"Chung Y-R, Ha KH, Lee K, Kim DJ (2019) Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: a real-world Korean study. PLoS ONE 14(10):e0224549","journal-title":"PLoS ONE"},{"issue":"10","key":"3768_CR15","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.oret.2024.05.003","volume":"8","author":"AJ Barkmeier","year":"2024","unstructured":"Barkmeier AJ, Herrin J, Swarna KS, Deng Y, Polley EC, Umpierrez GE et al (2024) Comparative effectiveness of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas for sight-threatening diabetic retinopathy. Ophthalmol Retina 8(10):943\u2013952","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"3768_CR16","volume":"2018","author":"EH Cho","year":"2018","unstructured":"Cho EH, Park SJ, Han S, Song JH, Lee K, Chung YR (2018) Potent oral hypoglycemic agents for microvascular complication: sodium-glucose cotransporter 2 inhibitors for diabetic retinopathy. J Diabetes Res 2018(1):6807219","journal-title":"J Diabetes Res"},{"issue":"10","key":"3768_CR17","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1111\/dom.15788","volume":"26","author":"DSH Lin","year":"2024","unstructured":"Lin DSH, Lo HY, Huang KC, Lin TT, Lee JK, Lin LY (2024) Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a population-based cohort study. Diabetes Obes Metab 26(10):4386\u20134396","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"3768_CR18","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jfo.2021.01.005","volume":"44","author":"MC Sabaner","year":"2021","unstructured":"Sabaner MC, Duman R, Dogan M, Akdogan M, Vurmaz A, Bozkurt E et al (2021) Do SGLT2 inhibitors prevent preclinical diabetic retinopathy? A prospective pilot optical coherence tomography angiography study. J Fr Ophtalmol 44(8):1159\u20131167","journal-title":"J Fr Ophtalmol"},{"issue":"1","key":"3768_CR19","doi-asserted-by":"crossref","first-page":"17049","DOI":"10.1038\/s41598-023-43893-2","volume":"13","author":"JX Li","year":"2023","unstructured":"Li JX, Hung YT, Bair H, Hsu SB, Hsu CY, Lin CJ (2023) Sodium-glucose co-transporter 2 inhibitor add-on therapy for metformin delays diabetic retinopathy progression in diabetes patients: a population-based cohort study. Sci Rep 13(1):17049","journal-title":"Sci Rep"},{"issue":"11","key":"3768_CR20","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s13300-024-01649-9","volume":"15","author":"M Koshizaka","year":"2024","unstructured":"Koshizaka M, Tatsumi T, Kiyonaga F, Kosakai Y, Yoshinaga Y, Shintani-Tachi M (2024) Comparison of the risk of diabetic retinopathy between sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus in Japan: a retrospective analysis of real-world data. Diabetes Ther 15(11):2401\u20132416. https:\/\/doi.org\/10.1007\/s13300-024-01649-9","journal-title":"Diabetes Ther"},{"issue":"1","key":"3768_CR21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jamaophthalmol.2024.5219","volume":"143","author":"H Tesfaye","year":"2024","unstructured":"Tesfaye H, Paik JM, Roh M, Htoo PT, Zakoul H, Schmedt N et al (2024) Empagliflozin and the risk of retinopathy in patients with type 2 diabetes. JAMA Ophthalmol 143(1):62\u201371","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"3768_CR22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/cpt.3074","volume":"115","author":"ST Huang","year":"2024","unstructured":"Huang ST, Bair PJ, Chang SS, Kao YN, Chen SN, Wang IK et al (2024) Risk of diabetic retinopathy in patients with type 2 diabetes after SGLT-2 inhibitors: a nationwide population cohort study. Clin Pharmacol Ther 115(1):95\u2013103","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3768_CR23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2174\/1574886318666230420084701","volume":"19","author":"J Hasselstr\u00f8m Jensen","year":"2024","unstructured":"Hasselstr\u00f8m Jensen J, Vestergaard P, Hasselstr\u00f8m Jensen M (2024) Association between glucose-lowering treatments and risk of diabetic retinopathy in people with type 2 diabetes: a nationwide cohort study. Curr Drug Saf 19(2):236\u2013243","journal-title":"Curr Drug Saf"},{"issue":"12","key":"3768_CR24","doi-asserted-by":"crossref","first-page":"e2348431","DOI":"10.1001\/jamanetworkopen.2023.48431","volume":"6","author":"FS Yen","year":"2023","unstructured":"Yen FS, Wei JCC, Yu TS, Hung YT, Hsu CC, Hwu CM (2023) Sodium-glucose cotransporter 2 inhibitors and risk of retinopathy in patients with type 2 diabetes. JAMA Netw Open 6(12):e2348431","journal-title":"JAMA Netw Open"},{"key":"3768_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06132-5","author":"A Eleftheriadou","year":"2024","unstructured":"Eleftheriadou A, Riley D, Zhao SS, Austin P, Hern\u00e1ndez G, Lip GY et al (2024) Risk of diabetic retinopathy and diabetic macular oedema with sodium\u2013glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Diabetologia. https:\/\/doi.org\/10.1007\/s00125-024-06132-5","journal-title":"Diabetologia"},{"key":"3768_CR26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","volume":"265","author":"KM Wai","year":"2024","unstructured":"Wai KM, Mishra K, Koo E, Ludwig CA, Parikh R, Mruthyunjaya P et al (2024) Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record data study. Am J Ophthalmol 265:39\u201347","journal-title":"Am J Ophthalmol"},{"key":"3768_CR27","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"4","key":"3768_CR28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.13105\/wjma.v5.i4.80","volume":"5","author":"C Luchini","year":"2017","unstructured":"Luchini C, Stubbs B, Solmi M, Veronese N (2017) Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa Scale. World J Meta-Anal 5(4):80\u201384","journal-title":"World J Meta-Anal"},{"issue":"4","key":"3768_CR29","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.2337\/dc18-1355","volume":"42","author":"SE Inzucchi","year":"2019","unstructured":"Inzucchi SE, Wanner C, Hehnke U, Zwiener I, Kaspers S, Clark D et al (2019) Retinopathy outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. Diabetes Care 42(4):e53\u2013e55","journal-title":"Diabetes Care"},{"issue":"3","key":"3768_CR30","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4093\/dmj.2022.0221","volume":"47","author":"TY Lin","year":"2023","unstructured":"Lin TY, Kang EY, Shao SC, Lai EC, Garg SJ, Chen KJ et al (2023) Risk of diabetic retinopathy between sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Diabetes Metab J 47(3):394\u2013404","journal-title":"Diabetes Metab J"},{"key":"3768_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100547","author":"JH Joo","year":"2024","unstructured":"Joo JH, Sharma N, Shaia J, Wu AK, Skugor M, Singh RP et al (2024) The effect of glucagon-like peptide-1 receptor agonists on diabetic retinopathy at a tertiary care center. Ophthalmol Sci. https:\/\/doi.org\/10.1016\/j.xops.2024.100547","journal-title":"Ophthalmol Sci"},{"key":"3768_CR32","doi-asserted-by":"crossref","unstructured":"Nandave M (2024) The history of the development of SGLT2 inhibitors for the treatment of diabetes: from biology to chemistry. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure: Mechanisms and Clinical Applications: A Machine-Generated Literature Overview, Springer, p. 1\u201332.","DOI":"10.1007\/978-981-97-7568-2_1"},{"issue":"1","key":"3768_CR33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","volume":"66","author":"V Vallon","year":"2015","unstructured":"Vallon V (2015) The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66(1):255\u2013270","journal-title":"Annu Rev Med"},{"issue":"22","key":"3768_CR34","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128","journal-title":"N Engl J Med"},{"issue":"21","key":"3768_CR35","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJ McMurray","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008","journal-title":"N Engl J Med"},{"issue":"5","key":"3768_CR36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","volume":"138","author":"K R\u00e5dholm","year":"2018","unstructured":"R\u00e5dholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D et al (2018) Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation 138(5):458\u2013468","journal-title":"Circulation"},{"issue":"23","key":"3768_CR37","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","volume":"142","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Cannon CP, Cherney DZ, Masiukiewicz U, Pratley R, Dagogo-Jack S et al (2020) Efficacy of ertugliflozin on heart failure\u2013related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation 142(23):2205\u20132215","journal-title":"Circulation"},{"issue":"4","key":"3768_CR38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","volume":"143","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CS et al (2021) Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation 143(4):337\u2013349","journal-title":"Circulation"},{"issue":"5","key":"3768_CR39","volume":"10","author":"YH Teo","year":"2021","unstructured":"Teo YH, Teo YN, Syn NL, Kow CS, Yoong CSY, Tan BY et al (2021) Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials. J Am Heart Assoc 10(5):e019463","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"3768_CR40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12933-023-02042-9","volume":"23","author":"J Chen","year":"2024","unstructured":"Chen J, Jiang C, Guo M, Zeng Y, Jiang Z, Zhang D et al (2024) Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol 23(1):2","journal-title":"Cardiovasc Diabetol"},{"key":"3768_CR41","doi-asserted-by":"crossref","first-page":"1273781","DOI":"10.3389\/fcvm.2023.1273781","volume":"10","author":"HA Cheema","year":"2023","unstructured":"Cheema HA, Shafiee A, Athar MMT, Rafiei MA, Mehmannavaz A, Jafarabady K et al (2023) Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med 10:1273781","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"3768_CR42","volume":"2020","author":"W Sha","year":"2020","unstructured":"Sha W, Wen S, Chen L, Xu B, Lei T, Zhou L (2020) The role of SGLT2 inhibitor on the treatment of diabetic retinopathy. J Diabetes Res 2020(1):8867875","journal-title":"J Diabetes Res"},{"key":"3768_CR43","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S233538","author":"BM Bonora","year":"2020","unstructured":"Bonora BM, Avogaro A, Fadini GP (2020) Extraglycemic effects of SGLT2 inhibitors: a review of the evidence. Diabetes Metab Syndr Obes. https:\/\/doi.org\/10.2147\/DMSO.S233538","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"11","key":"3768_CR44","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/hh1101.091265","volume":"88","author":"M Wakisaka","year":"2001","unstructured":"Wakisaka M, Kitazono T, Kato M, Nakamura U, Yoshioka M, Uchizono Y et al (2001) Sodium-coupled glucose transporter as a functional glucose sensor of retinal microvascular circulation. Circ Res 88(11):1183\u20131188","journal-title":"Circ Res"},{"issue":"8","key":"3768_CR45","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/glycob\/cwx047","volume":"27","author":"M Wakisaka","year":"2017","unstructured":"Wakisaka M, Nagao T (2017) Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy. Glycobiology 27(8):691\u2013695","journal-title":"Glycobiology"},{"key":"3768_CR46","doi-asserted-by":"publisher","DOI":"10.2337\/db19-588-P","author":"SP Leley","year":"2019","unstructured":"Leley SP, Luo Q, Alex AL, Bhatwadekar AD (2019) 588-P: diabetes leads to sodium-glucose cotransporter 2 (SGLT2) increase in the retina. Diabetes. https:\/\/doi.org\/10.2337\/db19-588-P","journal-title":"Diabetes"},{"issue":"11","key":"3768_CR47","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc15-2688","volume":"39","author":"G Daniele","year":"2016","unstructured":"Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D et al (2016) Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care 39(11):2036\u20132041","journal-title":"Diabetes Care"},{"issue":"4","key":"3768_CR48","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s10741-020-10065-7","volume":"26","author":"Y Hattori","year":"2021","unstructured":"Hattori Y (2021) Beneficial effects on kidney during treatment with sodium-glucose cotransporter 2 inhibitors: proposed role of ketone utilization. Heart Fail Rev 26(4):947\u2013952","journal-title":"Heart Fail Rev"},{"issue":"1","key":"3768_CR49","doi-asserted-by":"crossref","DOI":"10.12997\/jla.2022.11.1.1","volume":"11","author":"H Saucedo-Orozco","year":"2022","unstructured":"Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD (2022) SGLT2 inhibitors and ketone metabolism in heart failure. J Lipid Atheroscler 11(1):1","journal-title":"J Lipid Atheroscler"},{"issue":"1","key":"3768_CR50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211005","volume":"14","author":"MC Trotta","year":"2019","unstructured":"Trotta MC, Maisto R, Guida F, Boccella S, Luongo L, Balta C et al (2019) The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome. PLoS ONE 14(1):e0211005","journal-title":"PLoS ONE"},{"issue":"6116","key":"3768_CR51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","volume":"339","author":"T Shimazu","year":"2013","unstructured":"Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N et al (2013) Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339(6116):211\u2013214","journal-title":"Science"},{"issue":"5","key":"3768_CR52","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1210\/clinem\/dgab050","volume":"106","author":"S Mudaliar","year":"2021","unstructured":"Mudaliar S, Hupfeld C, Chao DL (2021) SGLT2 inhibitor-induced low-grade ketonemia ameliorates retinal hypoxia in diabetic retinopathy-a novel hypothesis. J Clin Endocrinol Metab 106(5):1235\u20131244","journal-title":"J Clin Endocrinol Metab"},{"key":"3768_CR53","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu Y, Xu Q, Li H, Meng Z, Hao M, Ma X et al (2022) Dapagliflozin reduces apoptosis of diabetic retina and human retinal microvascular endothelial cells through ERK1\/2\/cPLA2\/AA\/ROS pathway independent of hypoglycemic. Front Pharmacol 13:827896","journal-title":"Front Pharmacol"},{"key":"3768_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-016-0482-6","volume":"16","author":"C Ott","year":"2017","unstructured":"Ott C, Jumar A, Striepe K, Friedrich S, Karg MV, Bramlage P et al (2017) A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol 16:1\u20139","journal-title":"Cardiovasc Diabetol"},{"key":"3768_CR55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1475-2840-13-19","volume":"13","author":"C Ott","year":"2014","unstructured":"Ott C, Raff U, Schmidt S, Kistner I, Friedrich S, Bramlage P et al (2014) Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol 13:19","journal-title":"Cardiovasc Diabetol"},{"key":"3768_CR56","doi-asserted-by":"crossref","first-page":"204201882312223","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi SH (2024) Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab 15:20420188231222370","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"20","key":"3768_CR57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012428","volume":"23","author":"A Puddu","year":"2022","unstructured":"Puddu A, Maggi D (2022) Anti-inflammatory effects of GLP-1R activation in the retina. Int J Mol Sci 23(20):12428","journal-title":"Int J Mol Sci"},{"key":"3768_CR58","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.intimp.2018.10.040","volume":"66","author":"H Li","year":"2019","unstructured":"Li H, Zhang J, Lin L, Xu L (2019) Vascular protection of DPP-4 inhibitors in retinal endothelial cells in in vitro culture. Int Immunopharmacol 66:162\u2013168","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"3768_CR59","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41433-024-03472-9","volume":"39","author":"MS Varughese","year":"2024","unstructured":"Varughese MS, Varadhan L (2024) SGLT2 inhibitors and diabetic retinopathy: Insights from the management of nephropathy. Eye 39(2):213\u2013214","journal-title":"Eye"},{"issue":"5","key":"3768_CR60","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/dom.13232","volume":"20","author":"H Tang","year":"2018","unstructured":"Tang H, Li G, Zhao Y, Wang F, Gower EW, Shi L et al (2018) Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis. Diabetes Obes Metab 20(5):1262\u20131279","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3768_CR61","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/dom.14197","volume":"23","author":"C Li","year":"2021","unstructured":"Li C, Zhou Z, Neuen BL, Yu J, Huang Y, Young T et al (2021) Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 23(1):252\u2013257","journal-title":"Diabetes Obes Metab"},{"key":"3768_CR62","volume":"13","author":"B Zhou","year":"2022","unstructured":"Zhou B, Shi Y, Fu R, Ni H, Gu L, Si Y et al (2022) Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Front Endocrinol 13:907340","journal-title":"Front Endocrinol"},{"issue":"6","key":"3768_CR63","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13061797","volume":"13","author":"A Ma\u0142yszczak","year":"2024","unstructured":"Ma\u0142yszczak A, Prze\u017adziecka-Do\u0142yk J, Szyde\u0142ko-Pa\u015bko U, Misiuk-Hoj\u0142o M (2024) Novel antidiabetic drugs and the risk of diabetic retinopathy: a systematic review and meta-analysis of randomized controlled trials. J Clin Med 13(6):1797","journal-title":"J Clin Med"},{"issue":"10","key":"3768_CR64","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/17512433.2024.2399073","volume":"17","author":"B Xu","year":"2024","unstructured":"Xu B, Kang B, Tang F, Zhou J, He Z (2024) Association between sodium-glucose cotransporter 2 inhibitors and eye disorders: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 17(10):949\u2013957","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3768_CR65","doi-asserted-by":"crossref","first-page":"1303238","DOI":"10.3389\/fendo.2023.1303238","volume":"14","author":"L Tan","year":"2024","unstructured":"Tan L, Wang Z, Okoth K, Toulis KA, Denniston AK, Singh BM et al (2024) Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis. Front Endocrinol 14:1303238","journal-title":"Front Endocrinol"},{"issue":"7","key":"3768_CR66","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/17512433.2022.2102973","volume":"15","author":"Y Ma","year":"2022","unstructured":"Ma Y, Lin C, Cai X, Hu S, Zhu X, Lv F et al (2022) The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 15(7):877\u2013886","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03768-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03768-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03768-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:05:40Z","timestamp":1766167540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03768-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3768"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03768-z","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"406"}}